In DLBCL cases with positive HCV NS3 expression (strong and weak positive), as many as 30 samples were known to express CD30, with a cut-off of >0% in 8 (26.7%) samples and a cut-off of >20% in 3 (10.0%). DLBCL patients with positive HCV NS3 expression more often showed positive CD30 expression as well, although this result was not significant (Table 5). This evidence concerns the gene KRAS and diffuse large B-cell lymphoma.